Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.
The DESKTOP* III trial has shown that patients whose ovarian cancer recurs have better overall survival (OS) following secondary cytoreductive surgery plus platinum-based chemotherapy compared with a platinum-based chemotherapy regimen alone.
New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Niraparib maintenance therapy improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of time to progression since penultimate platinum chemotherapy or response to last chemotherapy, according to subgroup analyses of the NORA trial.
The PARP inhibitor rucaparib significantly improves progression-free survival (PFS) in patients with recurrent, advanced BRCA-positive ovarian cancer compared with standard-of-care chemotherapy, according to the ARIEL4 study presented at the SGO 2021 Meeting.
The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.
Frontline maintenance treatment with a DNA engineered autologous tumour cell (EATC) immunotherapy yields relapse-free survival (RFS) benefit in patients with advanced epithelial ovarian cancer, particularly in those with wild-type BRCA1/2 status, according to the VITAL* study presented at the 2020 SGO Annual Meeting.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.